Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that leading pharmaceutical companies that manufacture and market monoclonal antibodies (MAbs) are targeting smaller companies for acquisition in order to obtain the most promising cutting-edge technology in the development of MAbs.

Monoclonal antibodies are protein-based drugs that have dramatically changed the treatment of cancer over the past 20 years owing to their greater efficacy and tolerability when compared to more traditional chemotherapies. Roche and its partners Genentech and Chugai are the market leaders in the commercialization of MAbs for a number of diseases including cancer.

The new Spectrum report Industry Analysis -- How Companies Can Maintain the Market Success of Cancer MAbs finds that smaller, cash-poor companies on the leading edge of MAb development face an uncertain future as they will likely become acquisition targets and be forced to decide whether to attempt survival on licensing and royalties or to pursue their own product development. MAb-driven mergers over the past year include Amgen's acquisition of Abgenix, AstraZeneca's purchase of Cambridge Antibody Technology, and Merck's acquisition of Abmaxis. The report also finds that the premium pricing of monoclonal antibodies could cause significant marketing problems for drug developers in the years ahead.

"Cancer-targeting MAbs continue to push the limits in this market," said Matt Drapeau, an author of the report. "Their ever-soaring prices indicate that the breaking point is fast upon us. Payers must decide whether to reimburse potentially life-saving new treatments while wrestling with the reality of extraordinarily high priced MAbs. This situation does not bode well for drug manufacturers and could cause a backlash against the industry."

Industry Analysis -- How Companies Can Maintain the Market Success of Cancer MAbs is the first Spectrum report available in Decision Resources' new Spectrum online format. The new features of Spectrum online include easier navigation within reports, enhanced abstracts, and robust executive summaries.

Spectrum's enhanced report abstracts, tables of contents, and executive summaries highlight:

  * Comprehensive descriptions of report scope including companies mentioned   * Business implications that pinpoint the report's most relevant audiences   * Key strategic issues addressed in each report, tailored to specific     stakeholder groups   * Key tables and figures and related Spectrum reports   * Expertise of the author(s) and Decision Resources' program managers   * Forward-looking quotes from Decision Resources' program managers and     their biographies    About Spectrum 

Spectrum is an executive advisory service built on an extensive network of leading industry experts to deliver thought-provoking commentary and analysis of strategic business and technology issues shaping the global pharmaceutical and biotechnology markets.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Increased Use of Wyeth's Mylotarg and Launches of New Drugs Will More Than Double the Acute Myeloid Leukemia Market By 2015

View Now